

ESAOTE DISPLAYS NEXT GENERATION ULTRASOUND AND DEDICATED MRI TECHNOLOGY AT RSNA 2013

Genoa (ITALY), October 16th 2013 - **Esaote**, one of the world's leading manufacturers of medical diagnostic systems, presents its next generation of ultrasound and dedicated MRI imaging technology at RSNA 2013 to be held on December 1st-6th in Chicago (USA).

The **eHD** and **eXP** Technology, in Ultrasound and Dedicated MRI respectively, represent step-change innovations in the accuracy, quality, speed and flexibility of imaging technology.

"What we are displaying today represents a complete re-thinking and re-engineering of our technologies in Ultrasound and Dedicated MRI," said Carlos Faustmann – Chief Marketing Officer at Esaote. "Our vision, investment and intense technical focus has enabled the realisation of technology capable of serving the demands of medicine now and for another generation."



eHD Ultrasound Technology

eHD is the culmination of a complete re-engineering process through the probe, image capture, processing and display interfaces of Esaote's MyLab[™] ultrasound systems. eHD represents a stepchange in ultrasound diagnostic quality and flexibility.

At its core, the eHD Technology features the **eHD Pulser**, which generates the optimal ultrasound waveform beam for ultimate image clarity with no reduction in frame rate. eHD has also been applied to Esaote's **iQProbes** to improve transducer bandwidth and deliver increased signal sensitivity. A new appleprobe's grip configuration has also been introduced for greater operator control and comfort.

eHD features key software to reduce interference and deliver better visibility of internal structures for improved readability and diagnosis. Esaote's advanced Doppler technology has been updated with the introduction of **eHD CFM** which offers optimised vessel border detection with increased sensitivity and depth. For high resolution, high definition work, **eHD XFlow** is available to maximize spatial resolution and Doppler signal penetration.

Systems optimized with Esaote eHD Technology are designed to deliver a full range of clinical solutions, including advanced diagnosis, interventional and follow-up procedures. In particular, the MyLab[™]Twice with eHD Technology is an excellent match for all clinical needs, offering Virtual Navigator with Fusion Imaging, CnTI[™] Contrast Tuned Imaging for CEUS procedures, ElaXto-Elastosonography in all regions, and multi-dimensional 3D/4D imaging capability.

eXP MRI Technology

Already acknowledged as a world leader in musculoskeletal Dedicated MRI systems, eXP pushes Esaote's systems ever faster with more accurate acquisition and reconstruction processing for improved image quality. Scan times are dramatically reduced, as are overall power consumption and running costs.

To increase the speed of image acquisition and reconstruction, eXP combines powerful GPU hardware with advanced software, producing superior quality images with substantially reduced scan times. For example, Fast Spin Echo (FSE) sequences can be obtained up to 40 percent faster with **eXP Technology**.

eXP features combined methods to improve management of Echo Train Length and K-space acquisition to enhance overall image quality. Similarly, the use of Metallic Artifact Reduction (MAR) reduces artifacts and improves image quality when imaging patients with metallic implants.

eXP is available on the new G-Scan Brio, O-scan and S-scan Dedicated MRI systems. Full product demonstrations of eHD and eXP Technology are available at:

ESAOTE eHD TECHNOLOGY

ESAOTE eXP TECHNOLOGY

At RSNA 2013, Esaote also offers a new RIS/PACS Comprehensive Approach dedicated to supporting the entire Radiology Department workflow: **Suitestensa RIS PACS software platform** provides the workflow management in one Healthcare IT powerful solution, simplifying all phases of radiological activities.

Esaote will be exhibiting at the Radiological Society of North America 2013 Annual Meeting in **HALL A, SOUTH BUILDING, BOOTH number 3135**. To arrange an interview with a member of the senior marketing or engineering team please contact:

Jim Burch 714.473.544 E-mail: jburch@AltisimaMedia.com

About Esaote:

With about 325,3 millions euro consolidated sales in 2012 (70% of which coming from the international markets) the Esaote Group is leader in the sector of biomedical equipment (in particular, ultrasound, dedicated magnetic resonance and software to manage the diagnostic process). Today Esaote gives work to over 1360 employees, 20% of which employed in the R&D activities. Esaote is present with its industrial and research units in Italy (Genoa, Florence, Naples) in the Netherlands (Maastricht) and in China (Shenzhen). Esaote is internationally recognized to be one of the "Top Ten" world's leading diagnostic imaging companies. Esaote S.p.A. is owned by Ares (39,8%), IMI Investimenti of Intesa Sanpaolo Group (19,2%), Equinox (13.2%), MP Venture (13,2%), Carige (8,2%) and by 100 managers and directors of the Group (6.4%).

Information concerning Esaote and its products are available on the Internet site at the address http://www.esaote.com

Virtual Navigator is not available for sales in the USA.

The use of contrast agents in the USA is limited by FDA to left ventricle opacification and visualization of the left ventricular endocardial border.

ElaXto quantification is not for sales in the USA.

Technology and features are system/configuration dependent. Specifications subject to change without notice. Information might refer to products or modalities not yet approved in all countries. For further details, please contact your Esaote sales representative.